Secretan, Philippe-Henri Thirion, Olivier Saunier, Johanna Razazi, Keyvan Paul, Muriel Do, Bernard
Published in
Annales Pharmaceutiques Francaises
Lors de la première vague de contamination par le SARS-COV-2 en France, l'efficacité potentielle du lopinavir-ritonavir sur l'infection au Covid 19 a fait fortement augmenter la prescription du sirop Kaletra® au point de provoquer sa pénurie nationale. Dans les services de réanimation des hôpitaux parisiens en charge des patients présentant une con...
eynde, vanden
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin / the combination lopinavir/ritonavir / the combination with the addition of interferon β-1a / remdesivir. The trial was discontinued due to the lack of positive...
Karolyi, Mario Omid, Sara Pawelka, Erich Jilma, Bernd Stimpfl, Thomas Schoergenhofer, Christian Laferl, Hermann Seitz, Tamara Traugott, Marianna Wenisch, Christoph
...
Published in
Frontiers in Pharmacology
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing. Methods: COVID-19 positive patients admitted to the hospital who received high dose LPV/RTV were includ...
tanaudommongkon, irin tanaudommongkon, asama dong, xiaowei
Most antiretroviral medications for human immunodeficiency virus treatment and prevention require high levels of patient adherence, such that medications need to be administered daily without missing doses. Here, a long-acting subcutaneous injection of lopinavir (LPV) in combination with ritonavir (RTV) using in situ self-assembly nanoparticles (IS...
Di Castelnuovo, Augusto Costanzo, Simona Antinori, Andrea Berselli, Nausicaa Blandi, Lorenzo Bonaccio, Marialaura Bruno, Raffaele Cauda, Roberto Gialluisi, Alessandro Guaraldi, Giovanni
...
Published in
Frontiers in Medicine
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Study Design: Multicenter observational study of COVID-19 patients admitted in 33 I...
s. santos, andré l. braga-silva, lys a. gonçalves, diego s. ramos, lívia s. c. oliveira, simone s. p. souza, lucieri o. oliveira, vanessa s. lins, roberto d. pinto, marcia r. muñoz, julian e.
...
The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen Candida albicans by using in silico, in vitro and in vivo approaches in order to decipher its targets on fungal c...
Launay, Manon Demartin, Anne-Laure Ragey, Sophie Perinel Mismetti, Patrick Botelho-Nevers, Elisabeth Delavenne, Xavier
Published in
Therapeutic Drug Monitoring
In this article, we present a case of apixaban elimination prolonged by 450% in a patient with coronavirus disease 2019 because of multiple conditions, including drug–drug interaction, severe inflammation, and acute kidney injury. Therapeutic drug monitoring was used to explain unusual routine coagulation assays. This grand round highlights the imp...
Negrut, Nicoleta Codrean, Adriana Hodisan, Ioana Bungau, Simona Tit, Delia Mirela Marin, Ruxandra Behl, Tapan Banica, Florin Diaconu, Camelia C. Nistor-Cseppento, Delia Carmen
...
Published in
Experimental and Therapeutic Medicine
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is responsible for generating a global effort to discover urgent therapeutic solutions to limit the human damage caused by COVID-19. In the period of April to June 2020, 105 patients diagnosed with COVID-19 met the conditions for inclusion in the present study. They were trea...
Khorsandi, Zahra Afshinpour, Maral Molaei, Fatemeh Askandar, Rafee Habib Keshavarzipour, Fariba Abbasi, Maryam Sadeghi-Aliabadi, Hojjat
Published in
Journal of Biomolecular Structure & Dynamics
In response to the current pandemic caused by the novel SARS-CoV-2, we design new compounds based on Lopinavir structure as an FDA-approved antiviral agent which is currently under more evaluation in clinical trials for COVID-19 patients. This is the first example of the preparation of Lopinavir isosteres from the main core of Lopinavir conducted t...
eche, simeon kumar, ajit sonela, nelson gordon, michelle l.
Understanding the underlying molecular interaction during a therapy switch from lopinavir (LPV) to darunavir (DRV) is essential to achieve long-term virological suppression. We investigated the kinetic and structural characteristics of multidrug-resistant South African HIV-1 subtype C protease (HIV-1 PR) during therapy switch from LPV to DRV using ...
